AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27879176 — intervention group
Group type: COMPARATOR
Intervention: Exposure-Only Control (EOC)
Number of subjects: 45
Study 25703957 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session exercise-based rehabilitation program
Number of subjects: 20
Study 23497636 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg idursulfase beta infusions
Number of subjects: 31
Study 23497636 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg idursulfase beta infusions
Number of subjects: 31
Study 23497636 — intervention group
Group type: COMPARATOR
Intervention: Active comparator infusions
Number of subjects: 31
Study 21996523 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIIa
Number of subjects: 0
Study 21996523 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19634856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented metal-on-metal THA
Number of subjects: 200
Study 19634856 — intervention group
Group type: COMPARATOR
Intervention: Cemented metal-on-polyethylene THA
Number of subjects: 200
Study 16598490 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-coated STAR
Number of subjects: 109
Study 16598490 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-coated STAR
Number of subjects: 109
Study 16598490 — intervention group
Group type: COMPARATOR
Intervention: Single-coated STAR (last 31 cases)
Number of subjects: 109
Study 15182983 — intervention group
Group type: COMPARATOR
Intervention: Walking at predetermined velocities (0.17 to 1.72 m/s)
Number of subjects: 0
Study 11255055 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal sclerocorneal incision
Number of subjects: 100
Study 11255055 — intervention group
Group type: COMPARATOR
Intervention: Clear corneal incision
Number of subjects: 100
Study 9210530 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone supplementation (rhGH, 0.15 mg/kg/d)
Number of subjects: 24
Study 9210530 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition alone
Number of subjects: 24
Study 9210530 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with adjuvant rhGH
Number of subjects: 24
Study 8036601 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 43
Study 8036601 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 43
Study 8036601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 43
Study 8036601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (in patients resistant to other immunodepressants)
Number of subjects: 43
Study 3519885 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 100
Study 3519885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus aminoglutethimide (AG) and hydrocortisone (HC)
Number of subjects: 100
Study 3519885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) and hydrocortisone (HC) after TAM therapy
Number of subjects: 100
Study 31698085 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2, or 3 autodial reminders
Number of subjects: 120130
Study 31698085 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120130
Study 29127492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg dexmedetomidine (Dex-0.2 group)
Number of subjects: 137
Study 29127492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine (Dex-0.5 group)
Number of subjects: 137
Study 29127492 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 137
Study 25706950 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT plus reduced variety of high energy-dense foods (FBT+Variety)
Number of subjects: 24
Study 25706950 — intervention group
Group type: COMPARATOR
Intervention: Usual family based treatment (FBT)
Number of subjects: 24
Study 23237107 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks
Number of subjects: 682
Study 21040694 — intervention group
Group type: EXPERIMENTAL
Intervention: SC602 (1 × 10(6) CFU)
Number of subjects: 167
Study 21040694 — intervention group
Group type: EXPERIMENTAL
Intervention: SC602
Number of subjects: 167
Study 21040694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 18332052 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multifactorial falls prevention programme
Number of subjects: 3999
Study 18332052 — intervention group
Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 3999
Study 17178701 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus hypocaloric diet
Number of subjects: 71
Study 17178701 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 71
Study 15556325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg before surgery
Number of subjects: 34
Study 15556325 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection before surgery
Number of subjects: 34
Study 15556325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg after surgery
Number of subjects: 34
Study 15556325 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection after surgery
Number of subjects: 34
Study 10895410 — intervention group
Group type: EXPERIMENTAL
Intervention: r-tPA
Number of subjects: 39
Study 10895410 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Number of subjects: 39
Study 9322804 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg methimazole (MMI) + 1.5 micrograms 1 alpha (OH)D3 (group B)
Number of subjects: 30
Study 9322804 — intervention group
Group type: COMPARATOR
Intervention: 30 mg methimazole (MMI) (group A)
Number of subjects: 30
Study 7691269 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroperoxycyclophosphamide (4-HC) with WR-2721 (amifostine)
Number of subjects: 0
Study 7691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive selection of CD34+ hematopoietic progenitors
Number of subjects: 0
Study 7691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 7691269 — intervention group
Group type: COMPARATOR
Intervention: 4-hydroperoxycyclophosphamide (4-HC) alone
Number of subjects: 0
Study 3531038 — intervention group
Group type: EXPERIMENTAL
Intervention: Endralazine
Number of subjects: 20
Study 3531038 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 20
Study 30229852 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPro-UK thrombolysis
Number of subjects: 90
Study 30229852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (Solitaire scaffold)
Number of subjects: 90
Study 30229852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (rhPro-UK after Solitaire scaffold)
Number of subjects: 90
Study 30229852 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis group (rhPro-UK)
Number of subjects: 90
Study 30229852 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy group (Solitaire scaffold)
Number of subjects: 90
Study 26872105 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoaching
Number of subjects: 574
Study 26872105 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 574
Study 24924486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day for six months
Number of subjects: 144
Study 24924486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 22778302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cartoon movie with smoking characters
Number of subjects: 206
Study 22778302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to family-oriented movie with smoking characters
Number of subjects: 206
Study 22778302 — intervention group
Group type: COMPARATOR
Intervention: Exposure to cartoon movie without smoking characters
Number of subjects: 206
Study 22778302 — intervention group
Group type: COMPARATOR
Intervention: Exposure to family-oriented movie without smoking characters
Number of subjects: 206
Study 20426883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg)
Number of subjects: 22
Study 20426883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18693399 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathways (CP)
Number of subjects: 0
Study 18693399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 15885696 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole (MBZ)
Number of subjects: 470
Study 15885696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 15885696 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole (TBZ)
Number of subjects: 470
Study 12438289 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) grafts in patients with TDM
Number of subjects: 1526
Study 12438289 — intervention group
Group type: COMPARATOR
Intervention: Internal mammary artery (IMA) grafts in patients without TDM
Number of subjects: 1526
Study 12438289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein grafts in patients with TDM
Number of subjects: 1526
Study 12438289 — intervention group
Group type: COMPARATOR
Intervention: Vein grafts in patients without TDM
Number of subjects: 1526
Study 11535474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal Corneal Ring Segments (ICRS)
Number of subjects: 452
Study 9430799 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (HC)
Number of subjects: 9
Study 9430799 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (HF)
Number of subjects: 9
Study 9430799 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 9
Study 8213600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal propranolol spray (5 mg/puff)
Number of subjects: 16
Study 8213600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3619432 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin orally
Number of subjects: 8
Study 3619432 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin intravenously
Number of subjects: 8
Study 3619432 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin orally
Number of subjects: 8
Study 30558006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (HR) group, infused at a rate of 0.25 μg/kg/min, adjusted by 0.05 μg/kg/min as needed.
Number of subjects: 92
Study 30558006 — intervention group
Group type: COMPARATOR
Intervention: Low-dose remifentanil (LR) group, infused at a rate of 0.05 μg/kg/min.
Number of subjects: 92
Study 30558006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (HR) group.
Number of subjects: 92
Study 30558006 — intervention group
Group type: COMPARATOR
Intervention: Low-dose remifentanil (LR) group.
Number of subjects: 92
Study 30558006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HR and LR).
Number of subjects: 92
Study 27421815 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle aspiration (EUS-FNA)
Number of subjects: 22
Study 27421815 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle biopsy (EUS-FNB)
Number of subjects: 22
Study 25042870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg oral dose of risperidone
Number of subjects: 70
Study 22180560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine dosing according to WHO weight band
Number of subjects: 0
Study 22180560 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine dosing according to FDA label
Number of subjects: 0
Study 20600017 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon‐alfa‐2a (Peg‐IFNalfa‐2a) 180 µg/wk
Number of subjects: 933
Study 20600017 — intervention group
Group type: EXPERIMENTAL
Intervention: albinterferon alfa‐2b (albIFN) 900 µg every 2 weeks
Number of subjects: 933
Study 20600017 — intervention group
Group type: EXPERIMENTAL
Intervention: albinterferon alfa‐2b (albIFN) 1200 µg every 2 weeks
Number of subjects: 933
Study 18235117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 U subcutaneously once weekly for 24 weeks
Number of subjects: 463
Study 18235117 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 463
Study 18235117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 463
Study 16192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Murphy-tipped ETT without thermosoftening
Number of subjects: 100
Study 16192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill-tipped ETT without thermosoftening
Number of subjects: 100
Study 16192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Murphy-tipped ETT with thermosoftening
Number of subjects: 100
Study 16192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill-tipped ETT with thermosoftening
Number of subjects: 100
Study 16192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosoftening (applied to both ETT types)
Number of subjects: 100
Study 14623212 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction that simultaneously challenged children's beliefs concerning why the earth appears flat and the role of gravity
Number of subjects: 132
Study 14623212 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction that repeatedly challenged only one of these beliefs
Number of subjects: 132
Study 14623212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 132
Study 10851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented acetabular component
Number of subjects: 16
Study 10851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented acetabular component
Number of subjects: 16
Study 8927736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hepatitis A
Number of subjects: 40
Study 8927736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hepatitis B
Number of subjects: 40
Study 8927736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hepatitis C
Number of subjects: 40
Study 8927736 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 2055140 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day schedule of preoperative pelvic radiotherapy followed by immediate surgery
Number of subjects: 284
Study 2055140 — intervention group
Group type: COMPARATOR
Intervention: Control group (unirradiated patients)
Number of subjects: 284
Study 31513163 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation therapy during standard drug therapy (study group)
Number of subjects: 68
Study 31513163 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy (control group)
Number of subjects: 68
Study 28292320 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg three times a day
Number of subjects: 200
Study 28292320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26721135 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling combined with element calcium (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Number of subjects: 85
Study 26721135 — intervention group
Group type: COMPARATOR
Intervention: Control group (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Number of subjects: 85
Study 23797429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) cycle including interval endurance training on a cycle ergometer (3 times a week) and general fitness exercises and resistance training (2 times a week) for 6 months.
Number of subjects: 138
Study 23797429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CR).
Number of subjects: 138
Study 22099791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with CsA elimination
Number of subjects: 170
Study 22099791 — intervention group
Group type: COMPARATOR
Intervention: CsA minimization
Number of subjects: 170
Study 19154474 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal electromagnetic stimulation (ES)
Number of subjects: 70
Study 19154474 — intervention group
Group type: COMPARATOR
Intervention: Sham electromagnetic stimulation
Number of subjects: 70
Study 17923654 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 130
Study 17923654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 15182245 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted information recall
Number of subjects: 0
Study 15182245 — intervention group
Group type: COMPARATOR
Intervention: Non-enacted information recall
Number of subjects: 0
Study 11981075 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. calcium folinate (50 mg/week)
Number of subjects: 60
Study 11981075 — intervention group
Group type: EXPERIMENTAL
Intervention: oral calcium folinate (50 mg/week)
Number of subjects: 60
Study 11981075 — intervention group
Group type: COMPARATOR
Intervention: oral folic acid (45 mg/week)
Number of subjects: 60
Study 9615260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily for 12 months (group A)
Number of subjects: 66
Study 9615260 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 66
Study 7544827 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (r‐HuEpo)
Number of subjects: 15
Study 7544827 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 2696075 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Anterior Rhinomanometry (A.A.R.)
Number of subjects: 11
Study 2696075 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Anterior Rhinomanometry (P.A.R.)
Number of subjects: 11
Study 2696075 — intervention group
Group type: COMPARATOR
Intervention: Three methods of rhinomanometry
Number of subjects: 11
Study 383103 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 21657 (3X300 mg)
Number of subjects: 40
Study 383103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3X1 dragée)
Number of subjects: 40
Study 383103 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 21657
Number of subjects: 40
Study 383103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31487383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus prednisone (0.5 or 1.0 mg/kg/day, tapered over 3 or 6 months)
Number of subjects: 74
Study 31487383 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (1.0 or 1.5 mg/kg/day, tapered over 12 or 18 months)
Number of subjects: 74
Study 31487383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus prednisone
Number of subjects: 74
Study 31487383 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 74
Study 31644931 — intervention group
Group type: EXPERIMENTAL
Intervention: State high AMPA (approach-motivated positive affect)
Number of subjects: 165
Study 31644931 — intervention group
Group type: COMPARATOR
Intervention: State low AMPA
Number of subjects: 165
Study 31644931 — intervention group
Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 165
Study 31644931 — intervention group
Group type: EXPERIMENTAL
Intervention: State high AMPA
Number of subjects: 165
Study 28798049 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1305
Study 28798049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1305
Study 28798049 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1305
Study 26016150 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative external beam radiotherapy with hypofractionation regimes (3 fractions of 6.5 Gy for a total dose of 19.5 Gy, 4 fractions of 6.5 Gy for a total dose of 26 Gy) and standard treatment schedule (total dose of 26 Gy)
Number of subjects: 427
Study 26016150 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative external beam radiotherapy
Number of subjects: 427
Study 23720502 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amplitude occipital nerve stimulation (ONS)
Number of subjects: 0
Study 23720502 — intervention group
Group type: COMPARATOR
Intervention: Low-amplitude occipital nerve stimulation (ONS)
Number of subjects: 0
Study 21846380 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 401
Study 21846380 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 401
Study 19024003 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon
Number of subjects: 0
Study 16753121 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone sutures
Number of subjects: 770
Study 16753121 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 770
Study 15178171 — intervention group
Group type: EXPERIMENTAL
Intervention: Word naming task with Italian three-syllable words
Number of subjects: 0
Study 15178171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical-semantic impairment
Number of subjects: 0
Study 11127100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel (5 g twice daily for five days)
Number of subjects: 90
Study 11127100 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (500 mg twice daily for seven days)
Number of subjects: 90
Study 11127100 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 90
Study 11127100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 90
Study 9324103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1‐adrenoreceptor blocker (bunazosin)
Number of subjects: 43
Study 9324103 — intervention group
Group type: COMPARATOR
Intervention: Beta1‐adrenoreceptor blocker (metoprolol)
Number of subjects: 43
Study 8404944 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 80
Study 8404944 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 80
Study 3095093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 30
Study 3095093 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 30
Study 3095093 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30